Process to Identify and Obtain Codes for Items Potentially
Eligible for
Payment as New Technologies or Transitional Pass-Throughs Under
the
Outpatient Prospective Payment System
CPT codes and descriptions only are copyright 1999 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
I. BACKGROUND
We expect to implement a Medicare prospective payment system (PPS) for hospital outpatient services on July 1, 2000. One aspect of the outpatient PPS involves the recognition of new technology items and services as discrete payment groups under the PPS. The PPS will also provide for additional payments to hospitals at amounts higher than the amounts that would otherwise be paid under the PPS for certain drugs, biologicals, and medical devices, as provided for in the transitional pass-through payment provision under section 201(b) of the Balanced Budget Act of 1999 (BBRA). These are temporary payments for a period of 2 to 3 years. Actual hospital cost information gathered during this period will be used to appropriately assign the new technologies and the pass-through items to clinically related payment groups with comparable resource costs in the future.
In this document we describe, below, the process that we will use to (1) identify those items and services potentially eligible for such payments and (2) establish codes for them through the HCFA Common Procedure Coding System (HCPCS) that will be used to initiate payment and process claims for such items.
A large number of the items that may be treated as new technologies or for which payment may be made under the BBRA pass-through provision are already known to us through our own data gathering activities or through comments on the outpatient PPS proposed rule. Many of the items already have HCPCS codes, and we are taking steps to establish temporary codes for the remainder in an orderly fashion. We expect to be able to commence payments for some of these items as either new technologies or pass-throughs when the outpatient PPS is implemented on July 1, 2000 and for others possibly on October 1, 2000. These known items are listed, below, in section VI.
Other items potentially eligible for payment as new technologies or pass-throughs and not listed below are not known to us at this time. Therefore, we ask that interested parties take the steps outlined ,below, in sections III and IV to bring such items to our attention.
II. Potentially Eligible Items
A. New Technology Items and Services. New technology refers to--
1. an item or service that could not have been billed to the Medicare program as a hospital outpatient service in 1996 or, if it was billed in 1996, the costs of the item or service could not have been adequately represented in the 1996 data that we are using to construct the outpatient PPS rates; and,
2. an item or service that is not eligible for payment under the pass-through provision discussed under section II.B, immediately below.
B. Transitional Pass-through Items
Section 201(b) the BBRA 1999 requires us to make additional payments to hospitals for a period of 2 to 3 years for specific items at amounts higher than the amounts that would otherwise be paid under the hospital outpatient prospective payment system. The items designated by the law are the following:
1. Current orphan drugs, as designated under section 526 of the Federal Food, Drug, and Cosmetic Act
2. Current cancer therapy drugs, biologicals, and brachytherapy devices. These items are those drugs or biologicals that are used in cancer therapy including (but not limited to) chemotherapeutic agents, antiemetics, hematopoietic growth factors, colony stimulating factors, biological response modifiers, bisphosonates, and brachytherapy devices.
3. Current radiolpharmaceutical drugs and biological products used for diagnostic, monitoring, or therapeutic purposes.
4. New drugs, biologicals, or medical devices
In this context, Acurrent@ refers to those items for which hospital outpatient payment is being made on the first date the new PPS is implemented, that is on July 1, 2000. ANew@ refers to an item that was not paid as a hospital outpatient service prior to January 1, 1997 and for which the item=s cost is Anot insignificant@ in relation to the payment for the ambulatory payment classification group (APC) to which it is assigned. The specific criteria regarding the determination of not insignificant will be published in the forthcoming final rule on the hospital outpatient PPS. Until those criteria are published, submit items that meet the date requirement Additionally, new items are those that are not reflected in the 1996 claims data that we are required to use in developing the outpatient PPS.
III. Process for Identifying Items Potentially Eligible for Payment as New Technologies or Pass-Throughs
A manufacturer or other interested party who wishes to bring items that may be eligible for payment as new technologies or under the pass-through provision to our attention should mail their requests for consideration to the following address ONLY:
PPS New Tech/Pass-Throughs, Division of Practitioner and
Ambulatory Care
Mailstop C4-03-06
Health Care Financing
Administration
7500 Security Boulevard
Baltimore, MD 21244-1850.
To be considered, requests MUST include the following information:
IV. Process for Obtaining HCPCS Codes
We believe some items not yet known to us do not yet have assigned HCPCS codes. We expect to use national HCPCS codes in the hospital outpatient PPS to the greatest extent possible. These codes are established by a well-ordered process that operates on an annual cycle, starting with submission of information by interested parties due by April 1 and leading to announcement of new codes in October of each year.
Considering the exigencies of implementing a new system, we intend to establish temporary codes in 2000 to permit implementation of additional payments for other eligible items effective beginning October 1, 2000. The process for submitting information will be the same as for national codes.
For items that might be candidates for payment as new technologies or pass-throughs but that DO NOT have established HCPCS codes, submit the regular application for a national HCPCS code in accordance with the instructions found on the Internet at http://www.hcfa.gov/medicare/hcpcs.htm. Send applications for national HCPCS codes to --
C. Kaye Riley, HCPCS Coordinator, Health Care Financing
Administration
Mailstop C5-08-27
7500 Security Boulevard
Baltimore,
Maryland 21244-1850.
V. Deadlines for Submitting Requests
The deadline for submission of applications for a national HCPCS code for the calendar year 2001 cycle is April 1, 2000. The HCPCS process will proceed to assign national codes as warranted, and we expect these codes will be used in the hospital outpatient PPS starting January 1, 2001. Because the coding application will contain information vital to determining a specific item or product=s eligibility for new technology or pass-through payments, we are requesting that a copy of the national HCPCS coding application be sent concurrently to Attention: PPS New Tech/Pass-Throughs, Division of Practitioner and Ambulatory Care at the address specified, above, in section III.
This year, we plan to implement new technology payments and pass-through payments payment for appropriate items on October 1, 2000, if they come to our attention by April 1, 2000. We will use the same submissions made for national HCPCS codes as the basis for making temporary code assignments. A very large volume of requests or systems constraints could affect our ability to fully achieve this goal.
Any applications for HCPCS codes received after April 1, 2000 will be retained for the next cycle of the national HCPCS code assignment process starting April 1, 2001. However, we will also consider these items for assignment of temporary codes that may take effect in January 2001 or in a later quarterly update cycle.
How quickly additional payment for a new item can be implemented will depend on processing and systems constraints; it will in general require at least 6 months and may require as many as 9 months or possibly longer. Thus, for example, a submission that we receive in May (which is too late for October implementation) might get a temporary code to be used for implementing additional payments starting the following January.
Because of staffing and resource limitations, we cannot accept requests by either e-mail or facsimile (FAX) transmission.
VI. List of Known New Technology and Pass-Through Items
As indicated above, we expect to be able to commence payment for some of the new technology or pass-through items identified, below, when the outpatient PPS system is implemented on July 1, 2000 and for others possibly on October 1, 2000. However, we note that we are still evaluating the eligibility of a number of the items listed for payment as either new technologies or pass-through items.
Please note that HCPCS codes for drugs and radiopharmaceuticals listed below reflect the lowest dosages although payment for higher doses will be possible, as will be explained in the forthcoming final rule on the outpatient PPS.
Medicare Outpatient PPS Requests Received For | |
Recognition As New Technology Or Pass-Through | |
Payments | |
CPT/HCPCS | Description |
I. Pass-Through Items | |
A4642 | Satumomab pendetide per dose |
A9502 | Technetium Tc 99 M tetrofosmin |
A9600 | Strontium-89 chloride |
A9605 | Samarium sm 153 lexidronamm |
J0130 | Abciximab |
J0205 | Alglucerase injection |
J0207 | Amifostine |
J0256 | Alpha 1 proteinase inhibitor |
J0286 | Amphotericin B lipid complex |
J0476 | Baclofen intrathecal trial |
J0585 | Botulinum toxin a per unit |
J0640 | Leucovorin calcium injection |
J0735 | Clonidine hydrochloride |
J0850 | Cytomegalovirus imm IV /vial |
J1190 | Dexrazoxane HCl injection |
J1260 | Dolasetron mesylate |
J1325 | Epoprostenol injection |
J1436 | Etidronate disodium inj |
J1440 | Filgrastim 300 mcg injeciton |
J1561 | Immune globulin 500 mg |
J1562 | Immune globulin 5 gms |
J1565 | RSV-ivig |
J1620 | Gonadorelin hydroch/ 100 mcg |
J1626 | Granisetron HCl injection |
J1745 | Infliximab injection |
J1785 | imiglucerase /unit |
J1825 | Interferon beta-1a |
J1830 | Interferon beta-1b / .25 MG |
J1950 | Leuprolide acetate /3.75 MG |
J2275 | Morphine sulfate injection |
J2352 | Octreotide acetate injection |
J2355 | Oprelvekin injection |
J2405 | Ondansetron hcl injection |
J2430 | Pamidronate disodium /30 MG |
J2545 | Pentamidine isethionte/300mg |
J2765 | Metoclopramide hcl injection |
J2790 | Rho d immune globulin inj |
J2820 | Sargramostim injection |
J2994 | Retavase |
J3010 | Fentanyl citrate injeciton |
J3280 | Thiethylperazine maleate inj |
J3305 | Inj trimetrexate glucoronate |
J7190 | Factor viii |
J7191 | Factor VIII (porcine) |
J7192 | Factor viii recombinant |
J7194 | Factor ix complex |
J7197 | Antithrombin iii injection |
J7198 | Anti-inhibitor |
J7310 | Ganciclovir long act implant |
J7505 | Monoclonal antibodies |
J7913 | Daclizumab, Parenteral, 25 m |
J8510 | Oral busulfan |
J8520 | Capecitabine, oral, 150 mg |
J8530 | Cyclophosphamide oral 25 MG |
J8560 | Etoposide oral 50 MG |
J8600 | Melphalan oral 2 MG |
J8610 | Methotrexate oral 2.5 MG |
J9000 | Doxorubic hcl 10 MG vl chemo |
J9001 | Doxorubicin hcl liposome inj |
J9015 | Aldesleukin/single use vial |
J9020 | Asparaginase injection |
J9031 | Bcg live intravesical vac |
J9040 | Bleomycin sulfate injection |
J9045 | Carboplatin injection |
J9050 | Carmus bischl nitro inj |
J9060 | Cisplatin 10 MG injeciton |
J9065 | Cladribine per 1 MG |
J9070 | Cyclophosphamide 100 MG inj |
J9093 | Cyclophosphamide lyophilized |
J9100 | Cytarabine hcl 100 MG inj |
J9120 | Dactinomycin actinomycin d |
J9130 | Dacarbazine 10 MG inj |
J9150 | Daunorubicin |
J9151 | Daunorubicin citrate liposom |
J9165 | Diethylstilbestrol injection |
J9170 | Docetaxel |
J9181 | Etoposide 10 MG inj |
J9185 | Fludarabine phosphate inj |
J9190 | Fluorouracil injection |
J9200 | Floxuridine injection |
J9201 | Gemcitabine HCl |
J9202 | Goserelin acetate implant |
J9206 | Irinotecan injection |
J9208 | Ifosfomide injection |
J9209 | Mesna injection |
J9211 | Idarubicin hcl injeciton |
J9212 | Interferon alfacon-1 |
J9213 | Interferon alfa-2a inj |
J9214 | Interferon alfa-2b inj |
J9215 | Interferon alfa-n3 inj |
J9216 | Interferon gamma 1-b inj |
J9218 | Leuprolide acetate injeciton |
J9230 | Mechlorethamine hcl inj |
J9245 | Melphalan hydrochl 50 MG |
J9250 | Methotrexate sodium inj |
J9265 | Paclitaxel injection |
J9266 | Pegaspargase/singl dose vial |
J9268 | Pentostatin injection |
J9270 | Plicamycin (mithramycin) inj |
J9280 | Mitomycin 5 MG inj |
J9293 | Mitoxantrone hydrochl / 5 MG |
J9310 | Rituximab |
J9320 | Streptozocin injection |
J9340 | Thiotepa injection |
J9350 | Topotecan |
J9355 | Trastuzumab |
J9357 | Valrubicin |
J9360 | Vinblastine sulfate inj |
J9370 | Vincristine sulfate 1 MG inj |
J9390 | Vinorelbine tartrate/10 mg |
J9600 | Porfimer sodium |
Q0136 | Non esrd epoetin alpha inj |
Q0160 | Factor IX non-recombinant |
Q0161 | Factor IX recombinant |
Q0163 | Diphenhydramine HCl 50mg |
Q0164 | Prochlorperazine maleate 5mg |
Q0166 | Granisetron HCl 1 mg oral |
Q0167 | Dronabinol 2.5mg oral |
Q0169 | Promethazine HCl 12.5mg oral |
Q0171 | Chlorpromazine HCl 10mg oral |
Q0173 | Trimethobenzamide HCl 250mg |
Q0174 | Thiethylperazine maleate10mg |
Q0175 | Perphenazine 4mg oral |
Q0177 | Hydroxyzine pamoate 25mg |
Q0179 | Ondansetron HCl 8mg oral |
Q0180 | Dolasetron mesylate oral |
Q0187 | Factor viia recombinant |
Q2002 | Elliot's B solution |
Q2003 | Aprotinin, 10,000 kiu |
Q2004 | Treatment for bladder calcul |
Q2005 | Corticorelin ovine triflutat |
Q2006 | Digoxin immune FAB (Ovine), |
Q2007 | Ethanolamine oleate, 1000 ml |
Q2008 | Fomepizole, 1.5 G |
Q2009 | Fosphenytoin, 50 mg |
Q2010 | Glatiramer acetate, 25 mgeny |
Q2011 | Hemin, 1 mg |
Q2012 | Pegademase bovine inj 25 I.U |
Q2013 | Pentastarch 10% inj, 100 ml |
Q2014 | Sermorelin acetate, 0.5 mg |
Q2015 | Somatrem, 5 mg |
Q2016 | Somatropin, 1 mg |
Q2017 | Teniposide, 50 mg |
Q2018 | Urofollitropin, 75 I.U. |
Q2019 | Basiliximab |
Q2020 | Histrelin Acetate |
Q2021 | Lepirdin |
Q3001 | Brachytherapy Seeds |
Q3002 | Gallium Ga 67 |
Q3003 | Technetium Tc99m Bicisate |
Q3004 | Xenon Xe 133 |
II. New Technology | |
Items | |
53850 | Prostatic Microwave Thermotx |
53852 | Prostatic RF Thermotx |
78267 | Breath Tst Attain/Ciral, C-14 |
78268 | Breath Tst Anaylsis, C-14 |
G0125 | Lung Image (PET) |
G0126 | Lung Image (PET) Staging |
G0163 | PET for Rec of Colorectal Ca |
G0164 | PET for Lymphoma Staging |
G0165 | PET for Rec of Melanoma/MET Ca |
G0166 | Extrnl Counterpulse, Per Tx |
NeuroCybernetic Prosthesis System-Vagus Nerve Stimulator |
Last Updated March 9, 2000